AMG 509: This phase I trial is trying to understand how much immunotherapy is safe and effective for the treatment of castration-resistant prostate cancer that has spread to other parts of the bodyA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Summary

This is a dose exploration and expansion study. In the dose exploration phase, eligible patients will receive a short term intravenous (IV) infusion of AMG 509 to determine the recommended phase 2 dose (RP2D) or a maximum tolerate dose. In the dose expansion phase of the study, eligible patients will receive the RP2D of AMG 509, administered as a short term IV infusion. Dexamethasone will be administered in both the dose exploration and expansion phase, prior to cycle 1 dosing.